⚠️ For research and laboratory use only. Not for human or animal use.

penna retatrutide glp1 glucacone italia peptide

⚠️ For research and laboratory use only. Not for human or animal use.

Retatrutide – Pre-Filled Injectable Pen

320,00 €

The Retatrutide is a new multi-action peptide molecule
(GIP/GLP-1/GCGR), developed for research on metabolism,
body weight and glycemic control. The pre-filled
Pepticore Aminos pens are single-use, ready-to-use devices equipped
with a controlled delivery mechanism and a volume inspection window.

Product Features

Sterile, pre-filled pens ready for use.
Visible graduated scale for volume control.
Ideal for studies on metabolism, GIP/GLP-1/GCGR and
advanced pharmacological research.

Available Variants

Equivalent in 2 mg doses:

Variant	Total Content	Volume	2 mg Doses*
10 mg / 1 ml	10 mg	1.0 ml	5 doses

Indicative doses calculated based on 2 mg fractions each.

Note

Product intended exclusively for research use only.
Not intended for diagnosis, treatment, or prevention of diseases.

3 products 5% OFF

304,00 € / each ~~320,00 €~~

6 products 8% OFF

294,40 € / each ~~320,00 €~~

10 products 12% OFF

281,60 € / each ~~320,00 €~~

mg/ml

Clear

SKU: N/A Categories: Metabolic & Weight Loss, Ready-to-Use Peptides – Pens, Immune Support Brand: Pepticore Aminos

Laboratory analysis available (COA)Latest tested batch: PC-RET10-2610J — 10mg/1ml

Download latest COA

Pay With

Retatrutide — Tri-agonista GLP-1 / GIP / Glucagone

What is Retatrutide? Retatrutide (LY3437943) is a next-generation peptide belonging to the class of incretin mimetics. It acts simultaneously on three key hormonal receptors — GLP-1, GIP, and glucagon — aiming to synergistically modulate appetite, glucose metabolism, and energy expenditure. This triple mechanism positions it as the potential successor to tirzepatide, expanding the “dual agonist” concept into a new class of tri-agonists. All Pepticore Aminos products are strictly intended for research and laboratory use (Research Use Only).

How it works (GLP-1, GIP, Glucagon)

GLP-1 (glucagon-like peptide-1) sends satiety signals to the brain, slows gastric emptying, and stimulates insulin secretion in a glucose-dependent manner. It also helps reduce endogenous glucagon release, improving postprandial glucose control.

GIP (glucose-dependent insulinotropic polypeptide) enhances the insulin response after carbohydrate and fat intake, promoting glucose utilization for energy and reducing hepatic glucose production. Acting synergistically with GLP-1, it supports insulin sensitivity and lipid metabolism.

Glucagon in this context does not act as an insulin antagonist but as a regulator of energy metabolism. Its controlled activation increases lipolysis and fatty acid oxidation, promoting a higher resting energy expenditure and reduction of visceral fat. This triad of mechanisms makes retatrutide a unique research platform for studying complex metabolic balance.

🔬 Research Highlights

−24.2% mean body weight reduction after 48 weeks in adults with obesity (Phase 2, NEJM 2023)
−2.16 HbA1c points and ~17% weight loss in T2D after 36 weeks (Phase 2, Lancet 2023)
−81–82% liver fat reduction with normalization <5% in the MASLD substudy (Nature Medicine 2024)

Clinical Evidence (Phase 2)

Obesity without diabetes: In the New England Journal of Medicine study, retatrutide produced mean weight reductions of −22.8% (8 mg) and −24.2% (12 mg) after 48 weeks, along with improvements in BMI, waist circumference, and blood pressure. See NEJM 2023 / PubMed.

Type 2 Diabetes: In the Lancet Phase 2 trial, retatrutide reduced HbA1c by up to −2.16 percentage points at the highest doses, accompanied by a robust weight reduction (~17% at 36 weeks). The most frequent adverse events were gastrointestinal (nausea, reduced appetite), generally mild to moderate. See Lancet 2023 / PubMed.

Liver (MASLD): The Nature Medicine substudy reported a relative liver fat reduction of −81–82% at 8–12 mg doses, with normalization (<5%) in most participants and improvement in inflammation and liver function biomarkers. See Nature Medicine 2024 / PubMed.

Comparison with Semaglutide and Tirzepatide

Semaglutide (GLP-1 agonist) achieved ~15% mean weight loss over ~68 weeks; tirzepatide (GLP-1+GIP agonist) reached ~22.5% over ~72 weeks. Retatrutide, through additional glucagon receptor activation, achieved ~24% in 48 weeks. Although not head-to-head comparisons, these results show a progressive enhancement of efficacy across incretin-agonist generations, positioning retatrutide as a likely pharmacological evolution of tirzepatide.

Drug	Activated Receptors	Main Effects	Riduzione peso (durata)
Semaglutide	GLP-1	Satiety↑, delayed gastric emptying↓, improved glycemic control	~15% (≈68 weeks)*
Tirzepatide	GLP-1 + GIP	> Appetite↓, glucose↓, enhanced insulin response↑	~22,5% (≈72 weeks)*
Retatrutide	GLP-1 + GIP + glucagon	All of the above + increased energy expenditure↑; marked reduction in liver fat	~24% (48 weeks)

Values derived from different clinical studies (not head-to-head). Retatrutide data from NEJM 2023; tirzepatide and semaglutide from SURMOUNT and STEP trials.

Clinical status and registries

Retatrutide remains under clinical investigation. Multiple Phase 3 trials are ongoing in various populations (obesity, type 2 diabetes, weight maintenance, comorbid conditions). For official protocols, see:

References

Pepticore Aminos products are intended exclusively for research and laboratory use (Research Use Only). Not for human or animal consumption, nor for clinical or therapeutic use.

mg/ml	10mg/1ml

Peptide Technical Data

Product Name	Retatrutide
CAS Number	2381089-83-2
Sequence (Truncated)	His–Aib–Glu–Gly–Thr–Phe–Thr–Ser–Asp–Val–Ser–Ser–Tyr–Leu–Glu–Gly–Gln–Ala–Ala–Lys–Glu–Phe–Ile–Ala–Trp–Leu–Val–Arg–Gly–Arg–Gly–[modifications not publicly disclosed]
Molecular Formula	C₂₁₅H₃₄₀N₄₈O₆₄
Molecular Weight	~4710.55 g/mol
Purity	≥99% (HPLC validated)
Synthesis Method	Solid-phase peptide synthesis (SPPS)
Form	Lyophilized powder (1 vial)
Appearance	White to off-white lyophilized powder
Solubility	Soluble in sterile water or 1% acetic acid (~1–2 mg/mL typical)
Stability & Storage	−20°C stable up to 24 months; after reconstitution: 4°C ≤4 weeks or −20°C ≤6 months
Shipping Conditions	Ambient temperature during transit; store at −20°C upon receipt
Regulatory Status	Research use only; not for human consumption

Pens Storage

Storage Instructions – Pre-Filled Pens

Refrigeration: store at 2–8 °C to preserve quality and effectiveness.

Shelf life: the product maintains full stability and effectiveness for up to 12 months when properly refrigerated.

Temperature tolerance: the product remains stable up to 25 °C but should not be exposed to higher temperatures.

Avoid freezing: do not freeze; freezing may compromise the stability and effectiveness of the active ingredient.

Storage After Delivery

Store the pens in a refrigerated environment and away from direct light.

For use within a few weeks, regular household refrigeration (< 8 °C) is sufficient. Avoid direct exposure to heat sources.

Stability Notes

The pre-filled pens contain solutions already reconstituted and ready to use, therefore they require greater thermal care compared to lyophilized peptides.

Proper maintenance of the cold chain ensures maximum efficacy and molecular integrity of the active ingredient.

Disclaimer - For Research Use Only

I prodotti offerti da Pepticore Aminos sono destinati esclusivamente all’uso in ambito di ricerca e laboratorio e sono venduti unicamente a professionisti, istituti o enti qualificati. Tali prodotti non sono destinati al consumo umano o veterinario, né a qualsiasi applicazione che coinvolga organismi viventi, inclusi – a titolo esemplificativo – scopi diagnostici, terapeutici o ricreativi. By making a purchase, the customer declares that:

they are a qualified professional or entity, possessing the necessary competence, training, and facilities for the safe handling of chemical reagents;
they will use the product in full compliance with all applicable local, national, and European Union laws and regulations;
they will adopt appropriate safety measures during all stages of handling, storage, and disposal.

Prohibited uses:

The product must not be used as an Active Pharmaceutical Ingredient (API) in the manufacturing or preparation of medicines intended for humans or animals;
Any direct administration or use on humans or animals is strictly prohibited;
Pepticore Aminos does not endorse or permit the use of its products for the production, testing, or development of illegal substances.

Regulatory compliance: Pepticore Aminos non dichiara né implica che i prodotti siano approvati dall’Agenzia Europea per i Medicinali (EMA), dalla Food and Drug Administration (FDA) o da altre autorità regolatorie. Le informazioni riportate sono fornite esclusivamente a fini informativi e scientifici. Questi prodotti non sono destinati a diagnosticare, trattare, curare o prevenire alcuna malattia. Liability: L’acquirente si assume ogni responsabilità per la manipolazione, conservazione e utilizzo del prodotto in condizioni sicure e conformi alla legge. Pepticore Aminos non potrà essere ritenuta responsabile per danni diretti o indiretti derivanti da un uso improprio, dallo stoccaggio non corretto o da un utilizzo non autorizzato del prodotto. Pepticore Aminos si riserva il diritto di rifiutare la vendita a qualsiasi individuo o ente sospettato di uso improprio dei propri prodotti. In caso di dubbi sull’uso sicuro e legittimo del prodotto, si raccomanda di consultare un professionista qualificato esperto in ricerca di laboratorio.